NERV
Minerva Neurosciences, Inc.
Healthcare — Biotechnology
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
None
3 analysts
$3.23
$-0.12 (-3.58%)
Target:
$9.50
(194.1%)
Price History
52-Week Range
Sign in to add NERV to a watchlist or set price alerts.
Fundamentals
| Market Cap | $239.93M |
| P/E Ratio (TTM) | - |
| Forward P/E | -10.73 |
| EPS (TTM) | $-37.03 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $9.50 |
| Analysts | 3 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 57.2 |
| Beta | -0.17 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $12.46 |
| 52-Week Low | $1.59 |
| 50-Day Avg | $5.31 |
| 200-Day Avg | $4.77 |
| Avg Volume | 227.9K |
| Volume | 123.6K |
Performance Analysis
NEUTRALNERV presents a mixed picture with both positive and negative indicators.
~
Trading at 15% of its 52-week range.
+
RSI at 57.2 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none" from 3 analysts.
+
Average analyst target of $9.50 implies 194.1% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:22 UTC
Back to Screener Export Report